10:17 AM EST - HLS Therapeutics Inc. : Announces its financial results for the three months ended March 31, 2026. All amounts are in thousands of United States dollars unless otherwise stated. Q1 2026 revenue was $12.9 million, Adjusted EBITDA was $3.5 million and cash from operations was $6.4 million, compared to $12.6 million, $3.8 million and $3.5 million, respectively. HLS Therapeutics Inc.
shares T.HLS are trading unchanged at $4.67.
